Development of liquid chromatographic (LC) method for simultaneous estimation of novel anti diabetic drug Evogliptin and Metformin

Evogliptin and Metformin are antidiabetic medications. Evogliptin works by increasing the release of insulin from the pancreas and decreasing the hormones that raise blood sugar levels. This reduces the fasting and post-meal sugar levels. Metformin works by lowering glucose production in the liver, delaying the absorption of sugar (glucose) from the intestines, and increasing the body's sensitivity to insulin. Accurate and precise high performance liquid chromatographic method has been developed for the estimation of Metformin and Evogliptin. Agilent C18 Column (250mm x 4.6mm, 5µm particle size) was used as stationary phase and methanol: 0.11% acetic acid in water (31: 69 % V/V) was used as mobile phase. The method was linear in the concentration range 50-250 µg/mL and 0.5 to 2.5 µg/mL of Metformin and Evogliptin respectively with a correlation coefficient of 0.999. The proposed method was validated with respect to linearity, accuracy, precision, and robustness as per International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use ICH Q2 (R2) guideline. The method was successfully applied for the analysis of Metformin and Evogliptin